<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-US">
                        <id>https://faqsir.com/company/laboratorio-reig-jofre-sa/feed</id>
                                <link href="https://faqsir.com/company/laboratorio-reig-jofre-sa/feed" rel="self"></link>
            <link rel="hub" href="https://pubsubhubbub.appspot.com/" />
                                <title><![CDATA[Laboratorio Reig Jofre S.A. — Announcements]]></title>
                    
                                <subtitle>Laboratorio Reig Jofre S.A. (BME:RJF) announcements published on FAQSIR. AI-generated content. Paid-for issuer communication. Not investment advice. Published in partnership with Laboratorio Reig Jofre S.A.. Laboratorio Reig Jofre S.A. pays FAQSIR a subscription fee for this page.</subtitle>
                                                    <updated>2026-10-14T14:25:57+00:00</updated>
                        <entry>
            <title><![CDATA[REIG JOFRE reports €17.9 million EBITDA for H1 2026 as Toledo antibiotics line starts production]]></title>
            <link rel="alternate" href="https://faqsir.com/company/laboratorio-reig-jofre-sa/reig-jofre-reports-eur179-million-ebitda-for-h1-2026-as-toledo-antibiotics-line-starts-production" />
            <id>https://faqsir.com/3387</id>
            <author>
                <name><![CDATA[FAQSIR News Desk]]></name>
                    </author>
            <summary type="html">
                <![CDATA[REIG JOFRE reported higher EBITDA and net income in H1 2026, while its new penicillin-based injectable antibiotics line in Toledo received regulatory approval and began production. AI-generated content. Paid-for issuer communication. Not investment advice.]]>
            </summary>
                                                <category term="News" />
                        
            <category scheme="http://cv.iptc.org/newscodes/digitalsourcetype/" term="trainedAlgorithmicMedia" label="AI-generated content" />
            <rights type="text">AI-generated content. Paid-for issuer communication. Not investment advice.</rights>

            <published>2026-10-14T14:25:15+00:00</published>
            <updated>2026-10-14T14:25:15+00:00</updated>
        </entry>
            <entry>
            <title><![CDATA[REIG JOFRE begins European marketing of dalbavancin across nine countries]]></title>
            <link rel="alternate" href="https://faqsir.com/company/laboratorio-reig-jofre-sa/reig-jofre-begins-european-marketing-of-dalbavancin-across-nine-countries" />
            <id>https://faqsir.com/3386</id>
            <author>
                <name><![CDATA[FAQSIR News Desk]]></name>
                    </author>
            <summary type="html">
                <![CDATA[REIG JOFRE has added dalbavancin to its hospital anti-infectives portfolio, with the injectable antibiotic available across nine European countries. AI-generated content. Paid-for issuer communication. Not investment advice.]]>
            </summary>
                                                <category term="News" />
                        
            <category scheme="http://cv.iptc.org/newscodes/digitalsourcetype/" term="trainedAlgorithmicMedia" label="AI-generated content" />
            <rights type="text">AI-generated content. Paid-for issuer communication. Not investment advice.</rights>

            <published>2026-10-14T14:24:36+00:00</published>
            <updated>2026-10-14T14:24:36+00:00</updated>
        </entry>
            <entry>
            <title><![CDATA[REIG JOFRE Receives Recognition for VINCOBIOSIS® at Aesthetic Technology Awards]]></title>
            <link rel="alternate" href="https://faqsir.com/company/laboratorio-reig-jofre-sa/reig-jofre-receives-recognition-for-vincobiosis-at-aesthetic-technology-awards" />
            <id>https://faqsir.com/3384</id>
            <author>
                <name><![CDATA[FAQSIR News Desk]]></name>
                    </author>
            <summary type="html">
                <![CDATA[REIG JOFRE has received recognition at the 2nd Aesthetic Technology Awards for VINCOBIOSIS® and its contribution to scientific progress in health and aesthetics. AI-generated content. Paid-for issuer communication. Not investment advice.]]>
            </summary>
                                                <category term="News" />
                        
            <category scheme="http://cv.iptc.org/newscodes/digitalsourcetype/" term="trainedAlgorithmicMedia" label="AI-generated content" />
            <rights type="text">AI-generated content. Paid-for issuer communication. Not investment advice.</rights>

            <published>2026-10-14T14:24:11+00:00</published>
            <updated>2026-10-14T14:24:11+00:00</updated>
        </entry>
            <entry>
            <title><![CDATA[REIG JOFRE reports Q1 2026 revenue decrease as EBITDA rises 1%]]></title>
            <link rel="alternate" href="https://faqsir.com/company/laboratorio-reig-jofre-sa/reig-jofre-reports-q1-2026-revenue-decrease-as-ebitda-rises-1" />
            <id>https://faqsir.com/3385</id>
            <author>
                <name><![CDATA[FAQSIR News Desk]]></name>
                    </author>
            <summary type="html">
                <![CDATA[REIG JOFRE reported €86 million in Q1 2026 revenue, a decrease of 2% compared with Q1 2025, alongside consolidated EBITDA of €10 million. AI-generated content. Paid-for issuer communication. Not investment advice.]]>
            </summary>
                                                <category term="News" />
                        
            <category scheme="http://cv.iptc.org/newscodes/digitalsourcetype/" term="trainedAlgorithmicMedia" label="AI-generated content" />
            <rights type="text">AI-generated content. Paid-for issuer communication. Not investment advice.</rights>

            <published>2026-10-14T14:24:32+00:00</published>
            <updated>2026-10-14T14:24:32+00:00</updated>
        </entry>
            <entry>
            <title><![CDATA[REIG JOFRE reports €331.1M revenue for 2025 as Toledo upgrades weigh on antibiotics]]></title>
            <link rel="alternate" href="https://faqsir.com/company/laboratorio-reig-jofre-sa/reig-jofre-reports-eur3311m-revenue-for-2025-as-toledo-upgrades-weigh-on-antibiotics" />
            <id>https://faqsir.com/3390</id>
            <author>
                <name><![CDATA[FAQSIR News Desk]]></name>
                    </author>
            <summary type="html">
                <![CDATA[REIG JOFRE reported €331.1M in 2025 revenue, while upgrades to two Toledo production lines contributed to a 30% decline in its antibiotics business. AI-generated content. Paid-for issuer communication. Not investment advice.]]>
            </summary>
                                                <category term="News" />
                        
            <category scheme="http://cv.iptc.org/newscodes/digitalsourcetype/" term="trainedAlgorithmicMedia" label="AI-generated content" />
            <rights type="text">AI-generated content. Paid-for issuer communication. Not investment advice.</rights>

            <published>2026-10-14T14:25:57+00:00</published>
            <updated>2026-10-14T14:25:57+00:00</updated>
        </entry>
            <entry>
            <title><![CDATA[REIG JOFRE announces increase in Leanbio stake to 85% for 3.5 million euros]]></title>
            <link rel="alternate" href="https://faqsir.com/company/laboratorio-reig-jofre-sa/reig-jofre-announces-increase-in-leanbio-stake-to-85-for-35-million-euros" />
            <id>https://faqsir.com/3388</id>
            <author>
                <name><![CDATA[FAQSIR News Desk]]></name>
                    </author>
            <summary type="html">
                <![CDATA[REIG JOFRE has announced that it increased its stake in Barcelona-based biotechnology company Leanbio from 47% to 85% through a 3.5 million euro acquisition from existing shareholders. AI-generated content. Paid-for issuer communication. Not investment advice.]]>
            </summary>
                                                <category term="News" />
                        
            <category scheme="http://cv.iptc.org/newscodes/digitalsourcetype/" term="trainedAlgorithmicMedia" label="AI-generated content" />
            <rights type="text">AI-generated content. Paid-for issuer communication. Not investment advice.</rights>

            <published>2026-10-14T14:25:19+00:00</published>
            <updated>2026-10-14T14:25:19+00:00</updated>
        </entry>
            <entry>
            <title><![CDATA[REIG JOFRE reports €242 million revenue for first nine months of 2025]]></title>
            <link rel="alternate" href="https://faqsir.com/company/laboratorio-reig-jofre-sa/reig-jofre-reports-eur242-million-revenue-for-first-nine-months-of-2025" />
            <id>https://faqsir.com/3389</id>
            <author>
                <name><![CDATA[FAQSIR News Desk]]></name>
                    </author>
            <summary type="html">
                <![CDATA[REIG JOFRE reported €242 million in revenue for the first nine months of 2025 as temporary lower antibiotic production affected results during industrial upgrades in Toledo and Barcelona. AI-generated content. Paid-for issuer communication. Not investment advice.]]>
            </summary>
                                                <category term="News" />
                        
            <category scheme="http://cv.iptc.org/newscodes/digitalsourcetype/" term="trainedAlgorithmicMedia" label="AI-generated content" />
            <rights type="text">AI-generated content. Paid-for issuer communication. Not investment advice.</rights>

            <published>2026-10-14T14:25:27+00:00</published>
            <updated>2026-10-14T14:25:27+00:00</updated>
        </entry>
    </feed>
